OR WAIT null SECS
February 18, 2026
Video
Navar discusses the positive data from the phase 3 trial and emphasizes substantial treatment adherence throughout the 52-week period.
February 10, 2026
Article
Patients with severe hypertriglyceridemia and MASLD saw reductions in fasting triglyceride and improvements in remnant cholesterol and hepatic fat.
January 22, 2026
MacDougall discusses the Family Heart Foundation’s recent study indicating that very few adults with ASCVD are receiving guideline-directed therapy.
January 18, 2026
Recent research shows a substantial portion of US youths have increased risk of cardiometabolic diseases due to obesity and overweight.
January 16, 2026
A cohort study of patients from the Women’s Health Study has highlighted the direct correlation between lipoprotein(a) levels and cardiovascular risk in healthy patients.
January 10, 2026
Rosenson explains the data gained from a terminated phase 2b trial, highlighting evinacumab’s potential as a triglyceride-lowering therapy.
January 09, 2026
The Q4 recap for cardiology spotlights major FDA decisions, key clinical trial updates, and more.
January 06, 2026
Catch up with major FDA decisions, critical conference news, and more.
December 23, 2025
Catch up on the most impactful headlines in dyslipidemia from all of 2025 with our Year in Review.
December 15, 2025
FDA approves lerodalcibep, a groundbreaking PCSK9 inhibitor, offering a monthly injection for LDL cholesterol reduction in patients with HoFH.
